TP53 and pancreatic neoplasm: Since the expression of ligands for NKG2D and DNAM-1 receptors is shared in many solid tumors (21, 25), this type of prospective therapeutic approach is expected to be effective not only for NB but also for a broad spectrum of solid tumors with p53 dysfunction, such as colorectal, breast, ovarian, lung and pancreatic cancers (64).